当前位置:科学网首页 > 小柯机器人 >详情
多重植入式微装置检测可识别癌症免疫疗法和常规药物的协同组合
作者:小柯机器人 发布时间:2022/7/8 14:10:49

美国俄勒冈健康与科学大学Joe W. Gray、哈佛医学院Oliver Jonas等研究人员合作发现,多重植入式微装置检测可识别癌症免疫疗法和常规药物的协同组合。相关论文于2022年7月4日在线发表于国际学术期刊《自然—生物技术》。

研究人员整合了高通量和高内涵的技术,一种可植入的微型装置,能够以纳米剂量将多种药物注入肿瘤的不同部位,并对肿瘤微环境状态进行多重成像,进而研究肿瘤细胞和免疫学对不同治疗方案的反应特征。利用乳腺癌的小鼠模型,研究人员在几天内从众多药物中确定了有效的组合。在三个免疫能力强的乳腺癌模型中的体内研究表明,预测的组合能协同提高疗效。
 
研究人员确定了至少五种有希望的治疗策略,其中panobinostat、venetoclax和抗CD40三联疗法在诱导整个模型的肿瘤完全缓解方面最为有效。成功的药物组合在免疫性细胞死亡过程中增加了癌症干细胞与树突状细胞的空间关联,并表明这是长期乳腺癌控制的重要作用机制。
 
据介绍,系统地确定癌症治疗中靶向药物和免疫疗法的协同组合仍然是困难的。
 
附:英文原文

Title: A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs

Author: Tatarova, Zuzana, Blumberg, Dylan C., Korkola, James E., Heiser, Laura M., Muschler, John L., Schedin, Pepper J., Ahn, Sebastian W., Mills, Gordon B., Coussens, Lisa M., Jonas, Oliver, Gray, Joe W.

Issue&Volume: 2022-07-04

Abstract: Systematically identifying synergistic combinations of targeted agents and immunotherapies for cancer treatments remains difficult. In this study, we integrated high-throughput and high-content techniques—an implantable microdevice to administer multiple drugs into different sites in tumors at nanodoses and multiplexed imaging of tumor microenvironmental states—to investigate the tumor cell and immunological response signatures to different treatment regimens. Using a mouse model of breast cancer, we identified effective combinations from among numerous agents within days. In vivo studies in three immunocompetent mammary carcinoma models demonstrated that the predicted combinations synergistically increased therapeutic efficacy. We identified at least five promising treatment strategies, of which the panobinostat, venetoclax and anti-CD40 triple therapy was the most effective in inducing complete tumor remission across models. Successful drug combinations increased spatial association of cancer stem cells with dendritic cells during immunogenic cell death, suggesting this as an important mechanism of action in long-term breast cancer control.

DOI: 10.1038/s41587-022-01379-y

Source: https://www.nature.com/articles/s41587-022-01379-y

期刊信息

Nature Biotechnology:《自然—生物技术》,创刊于1996年。隶属于施普林格·自然出版集团,最新IF:31.864
官方网址:https://www.nature.com/nbt/
投稿链接:https://mts-nbt.nature.com/cgi-bin/main.plex